Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Recurrence 2 Ovarian Neoplasms 2 Myeloproliferative Disorders 2 Myelodysplastic Syndromes 2 Lymphoma, Mantle-Cell 2 Leukemia, Myelomonocytic, Chronic 2 Leukemia, Myeloid, Acute 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Skin Neoplasms 1 Prostatic Neoplasms 1 Neoplasm Metastasis 1 Myeloid Malignancy 1 Melanoma 1 MDS 1 Lymphoma, Non-Hodgkin 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hematologic Neoplasms 1 Esophageal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 160 Fluorouracil 134 Paclitaxel 125 Radiotherapy 117 Oxaliplatin 87 Carboplatin 71 Docetaxel 70 Irinotecan 59 pembrolizumab 57 Capecitabine 57 Leucovorin 56 Radiation 47 Surgical Procedures, Operative 33 Drug Therapy 33 Esophagectomy 31 Cetuximab 25 Neoadjuvant Therapy 24 Nivolumab 23 Bevacizumab 21 Trastuzumab 20 camrelizumab 19 S 1 (combination) 19 Chemoradiotherapy 17 Albumin-Bound Paclitaxel 16 Magnetic Resonance Spectroscopy 15 Epirubicin 15 tislelizumab 14 Taxes 13 Radiotherapy, Intensity-Modulated 13 Cyclophosphamide 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Esophageal Neoplasms × eprenetapopt × Clear all

NCT02999893 2021-12-13

APROC

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Terminated

Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡